Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) announced ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. Benzinga Senior Editor Zepbound Put Eli Lilly On Top — Now ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

From a technical perspective, both stocks show strong bullish trends ... While both Novo Nordisk and Eli Lilly are poised to dominate the obesity-drug market, their strategic expansions into ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co ... recent prescription trends have shown promising results, with an increase in market share and total ...

Eli Lilly (NYSE ... This has helped Lilly's revenue soar -- and the share price followed. Though Lilly shares the market with rival big pharma Novo Nordisk, both companies are excelling, with ...

Eli Lilly LLY1.28%increase; green up pointing triangle isn’t your typical Big Pharma company. While the industry stares down a scary patent cliff, it has bucked the trend with a pipeline of ...

Eli Lilly's Current Market Status With a volume of 324,237, the price of LLY is up 1.72% at $851.42. RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.